The report focuses on the WTO accession of China and the impact it has had on the Chinese pharmaceutical industry, trends in the industry, competition in t…
The domestic pharmaceutical market is highly fragmented and inefficient. China, as of 2007, has around 3,000 to 6,000 domestic pharmaceutical manufacturers and around 14,000 domestic pharmaceutical distributors. Most often cited adverse factors include a lack of protection of intellectual property rights, a lack of visibility for drug approval procedures, a lack of effective governmental incentives, poor corporate support for drug research and differences in the treatment in China accorded to local and foreign firms.
Even so, the industry environment has been transformed for the better over the last 10 years. Entry to the WTO has brought a stronger patent system, medical insurance is now more widespread, and pharmaceutical-related regulations have been stiffened. China is reportedly expected to become the fifth largest pharmaceuticals market in the world by 2010.
Currently China has about 3,500 drug companies, falling from more than 5,000 in 2004, according to government figures. The number is expected to drop further. The domestic companies compete in the $10 billion market without a dominant leader. As of 2007, China is the world’s ninth drug market, and in 2008 it will become the eighth largest market.
China’s thousands of domestic companies account for 70% of the market, and the top 10 companies about 20%, according to Business China. In contrast, the top 10 companies in most developed countries control about half the market. Since June 30, 2004, the State Food and Drug Administration (SFDA) has been closing down manufacturers that do not meet the new GMP standards. Foreign players account for 10% to 20% of overall sales, depending on the types of medicines and ventures included in the count. But sales at the top-tier Chinese companies are growing faster than at Western ones.
This report examines the Chinese Pharmaceutical Industry from the basics onwards. The report focuses on the WTO accession of China and the impact it has had on the Chinese pharmaceutical industry, trends in the industry, competition in the industry, etc.
The report also analyzes the Chinese pharmaceutical industry through a SWOT analysis and a PEST analysis. The report looks at the investment scenario in the Chinese pharmaceutical industry and the role of the government in the industry and other factors.
A look at the top market players in the Chinese pharmaceutical industry completes this research report.
Table Of Contents :
Executive Summary 4
Global Pharmaceutical Industry Introduction 5 Industry Definition 5 Market Overview 5 Market Forecast 8
China’s Pharmaceutical Industry 9 Industry Definition 9 Industry Overview 9 Industry Segmentation 10 Competitive Scenario 10 Growth Factors Affecting the Industry 12 Issues Facing the Industry 13
Analysis of China’s OTC Pharmaceutical Market 15 Market Definition 15 Market Overview 15 Market Segments 15 Competitive Scenario 16 Sector Forecast 18
Analysis of China’s Generics Market 19 Market Definition 19 Market Overview 19 Market Segments 19 Competitive Scenario 20 Sector Forecast 21
Analysis of the Major Market Trends 23
SWOT Analysis of China’s Pharmaceutical Industry 26 Strengths 26 Weaknesses 26 Opportunities 26 Threats 27
PEST Analysis of China’s Pharmaceutical Industry 28 Political Features 28 Economic Features 29 Social Features 30 Technology Features 31
Investing in China’s Pharmaceutical Industry 33 Distribution Systems 33 Hospitals vs. Pharmacies 34 OTC Sector 35 Drug Pricing Policy in China 36 Market Consolidation 37 Outlook for Sector Investment 38
Chinese Pharma’s Contract Research Services 41
Outlook of Chinese Pharmaceutical Industry 44
Major Players in the Industry 47 AstraZeneca PLC 47 Beijing Double-Crane Pharmaceutical (DCPC) 50 Beijing TongRenTang Co., Ltd. 50 GlaxoSmithKline Plc 51 Northeast Pharmaceutical Group (NEPG) 52 Pfizer Inc 52 Sanjiu Medical and Pharmaceutical Co. Ltd. (SMPCL) 53 Shanghai Pharmaceutical Co. Ltd 54
List of Figures & Tables
Figure 1: Drug Market Trends (1998-2008) 44 Figure 2: Healthcare Expenditure Trends (1998-2007) 55 Figure 3: National Income & Drug Market Expenditure 56 Figure 4: OTC and Hospital Sourced Drug Market Trends, $bn (1998-2008) 56 Figure 5: Generics Market Trends (1998-2008) 57
Table 1: China OTC Pharmaceuticals Market Segmentation – Value, 2007 15 Table 2: China OTC Pharmaceuticals Market Segmentation on a Global Scenario – Value, 200716 Table 3: China OTC Pharmaceuticals Forecast in U.S.$ 18 Table 4: China Generics Market Segmentation – Value, 2006 19 Table 5: China Generics Market Segmentation on a Global Scenario – Value, 2006 20 Table 6: China Generics Market Value Forecast in U.S.$ 22 Table 7: China Drug Market Indicators 55 Table 8: Health Expenditure Indicators 55
To know more about this report & to buy a copy please visit :
Visionshopsters Ph : 91-22-40583000 Emailid: